Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elvis Ruznic"'
Autor:
Markus Stana, Brane Grambozov, Christoph Gaisberger, Josef Karner, Elvis Ruznic, Johannes Berchtold, Barbara Zellinger, Raphaela Moosbrugger, Michael Studnicka, Gerd Fastner, Felix Sedlmayer, Franz Zehentmayr
Publikováno v:
Diagnostics, Vol 12, Iss 5, p 1027 (2022)
Introduction: Curatively intended chemo-radio-immunotherapy for non-small cell lung cancer (NSCLC) stage III may lead to post-therapeutic pulmonary function (PF) impairment. We hypothesized that the decrease in global PF corresponds to the increase i
Externí odkaz:
https://doaj.org/article/17f835776eb44eb987ecd2ec8b1133ce
Autor:
Markus Stana, Brane Grambozov, Josef Karner, Isabella Gollner, Christoph Gaisberger, Elvis Ruznic, Barbara Zellinger, Raphaela Moosbrugger, Michael Studnicka, Gerd Fastner, Felix Sedlmayer, Franz Zehentmayr
Publikováno v:
Cancers; Volume 15; Issue 7; Pages: 1966
Introduction: Durvalumab following chemoradiotherapy (CRT) for non-small cell lung cancer stage III has become the standard of care (SoC) in the past few years. With this regimen, 5-year overall survival (OS) has risen to 43%. Therefore, adequate pul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef93b16305555ec0572065de337402b
Autor:
Barbara Zellinger, Ulrich Bodenhofer, Immanuela A. Engländer, Cornelia Kronberger, Brane Grambozov, Elvis Ruznic, Markus Stana, Josef Karner, Gerd Fastner, Karl Sotlar, Felix Sedlmayer, Franz Zehentmayr
Publikováno v:
Breast Cancer. 29:274-286
Background MicroRNAs are small non-coding RNAs with pivotal regulatory functions in multiple cellular processes. Their significance as molecular predictors for breast cancer was demonstrated in the past 15 years. The aim of this study was to elucidat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b999addcea180074d9f56cc356fc752a
https://doi.org/10.1007/s12282-021-01308-y
https://doi.org/10.1007/s12282-021-01308-y
Autor:
Brane Grambozov, Markus Stana, Bernhard Kaiser, Josef Karner, Sabine Gerum, Elvis Ruznic, Barbara Zellinger, Raphaela Moosbrugger, Michael Studnicka, Gerd Fastner, Felix Sedlmayer, Franz Zehentmayr
Publikováno v:
Cancers, Vol 14, Iss 573, p 573 (2022)
Introduction: Thoracic re-irradiation for recurrent lung cancer dates back four decades, when the first small series on 29 patients receiving palliative doses was published. With 5-year overall survival rates of 57% in PDL-1 positive patients after p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb36bfa0878b99062585e5f9ecb475f3
https://www.mdpi.com/2072-6694/14/3/573
https://www.mdpi.com/2072-6694/14/3/573